Immunotherapy provided very encouraging data on survival for MSI-H/dMMR mCRC and might be the best area of research, even for MSS POLE-1 or POLD1 mutant cancers, due to their high mutational burden [134,135,136,137,138,139]. Here, POLD1 is linked to cancer.